zur Navigation zum Inhalt
Onkologie 30. Juni 2011

Indolent lymphomas and mantle cell lymphoma: New developments as of ASH 2010

Recent clinical data presented at the Annual Meeting of the American Society of Hematology suggest that rituximab may challenge the role of watch & wait in the management of patients with advanced stage, asymptomatic follicular lymphoma. Other trials confirmed the activity of immuno-chemotherapy, in particular bendamustine plus rituximab, in indolent B-cell lymphomas. A new standard of care emerged for young patients with newly diagnosed mantle cell lymphoma: Incorporation of a cytarabine-containing regimen in the induction treatment improves the depth of response, which eventually also prolongs progression-free survival following autologous stem cell transplantation.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben